This article first appeared on GuruFocus .
Evaluating the Sustainability of Astellas Pharma's Upcoming Payout
Astellas Pharma Inc ( ALPMF ) recently announced a total dividend of $0.25 per share, with the ex-dividend date set for 2026-09-29. This distribution consists of $0.25 per share in cash dividends. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using data from GuruFocus, let's look into Astellas Pharma Inc's dividend performance and assess its sustainability. For value investors, understanding the mechanics behind this payout is essential for determining whether the stock aligns with a long-term income strategy.
What Does Astellas Pharma Inc Do?
-
This Powerful Chart Made Peter Lynch 29% A Year For 13 Years
-
How to calculate the intrinsic value of a stock?
-
Is ALPMF fairly valued? Test your thesis with our free DCF calculator.
Astellas Pharma Inc is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription drugs. Its main therapeutic areas include oncology, urology, immunology, and nephrology, along with a focus on regenerative medicine and gene therapy. Key products include XTANDI for prostate cancer, XOSPATA for leukemia, PADCEV for urothelial cancer, VEOZAH for menopausal vasomotor symptoms, Betanis/Myrbetriq/BETMIGA for overactive bladder, and Prograf, an immunosuppressant used in organ transplantation. The company sells primarily to healthcare providers, hospitals, and pharmacies through its own sales forces and partnerships with other pharmaceutical firms. Astellas operates in Japan, the Americas, Europe, and Asia, generating revenue mainly from product sales, with royalties and licensing income also contributing. It invests heavily in research and development and pursues collaborations and acquisitions to expand its pipeline.
A Glimpse at Astellas Pharma Inc's Dividend History
Astellas Pharma Inc has maintained a consistent dividend payment record since 2013. Dividends are currently distributed on a bi-annually basis. This consistent schedule provides reliable income for shareholders and demonstrates a disciplined approach to capital return. Below is a chart showing annual Dividends Per Share for tracking historical trends.
Breaking Down Astellas Pharma Inc's Dividend Yield and Growth
As of today, Astellas Pharma Inc currently has a 12-month trailing dividend yield of 3.02% and a 12-month forward dividend yield of 3.09%. This suggests an expectation of increased dividend payments over the next 12 months. Over the past three years, Astellas Pharma Inc's annual dividend growth rate was 9.10%. Extended to a five-year horizon, this rate increased to 13.50% per year. And over the past decade, Astellas Pharma Inc's annual dividends per share growth rate stands at an impressive 10.20%. Based on Astellas Pharma Inc's dividend yield and five-year growth rate, the 5-year yield on cost of Astellas Pharma Inc stock as of today is approximately 5.69%.
The Sustainability Question: Payout Ratio and Profitability
To assess the sustainability of the dividend, one needs to evaluate the company's payout ratio. The dividend payout ratio provides insights into the portion of earnings the company distributes as dividends. A lower ratio suggests that the company retains a significant part of its earnings, thereby ensuring the availability of funds for future growth and unexpected downturns. As of 2026-06-30, Astellas Pharma Inc's dividend payout ratio is 0.39. Astellas Pharma Inc's profitability rank offers an understanding of the company's earnings prowess relative to its peers. GuruFocus ranks Astellas Pharma Inc's profitability 9 out of 10 as of 2026-06-30, suggesting good profitability prospects. The company has reported positive net income for each year over the past decade, further solidifying its high profitability.
Growth Metrics: The Future Outlook
To ensure the sustainability of dividends, a company must have robust growth metrics. Astellas Pharma Inc's growth rank of 9 out of 10 suggests that the company's growth trajectory is good relative to its competitors. Revenue is the lifeblood of any company, and Astellas Pharma Inc's revenue per share , combined with the 3-year revenue growth rate , indicates a strong revenue model. Astellas Pharma Inc's revenue has increased by approximately 12.70% per year on average, a rate that outperforms approximately 77.87% of global competitors. The company's 3-year EPS growth rate showcases its capability to grow its earnings, a critical component for sustaining dividends in the long run. During the past three years, Astellas Pharma Inc's earnings increased by approximately 18.10% per year on average, a rate that outperforms approximately 62.1% of global competitors. Lastly, the company's 5-year EBITDA growth rate of 6.30%, which outperforms approximately 45.17% of global competitors.
Next Steps for Income-Focused Investors
In conclusion, Astellas Pharma Inc presents a compelling case for income-focused investors. The company combines a solid dividend yield of over 3% with a consistent history of growth, supported by a conservative payout ratio of 0.39 and high profitability and growth ranks. The double-digit dividend growth rates over the past decade, alongside robust revenue and earnings expansion, suggest that the current dividend level is well-supported by underlying business performance. While no investment is without risk, particularly in the pharmaceutical sector where patent cliffs and regulatory changes are constant threats, Astellas Pharma Inc's strong pipeline and financial discipline provide a margin of safety. For those looking to enhance their portfolio's income stream, monitoring Astellas Pharma Inc's upcoming ex-dividend date and future earnings reports could prove beneficial. GuruFocus Premium users can screen for high-dividend yield stocks using the High Dividend Yield Screener .
